- CA$9.02m
- CA$6.04m
- $26.61m
Brief: Innocan Pharma Announces Promising Results Of LPT-CBD Administered To Gottingen Minipigs
Brief: Innocan Pharma Corp - Liposomal Cbd Injection Technology Patent Allowed In Japan
Brief: Innocan Pharma Corp Now Sees U.S IPO Of 1.1 Million Units - SEC Filing
Brief: Innocan Pharma Announces Details Of Proposed Share Consolidation
Brief: Innocan Pharma Announces First Half Of 2025 Financial Results
Brief: Innocan Pharma Announces First Half Of 2025 Financial Results
Brief: Innocan Pharma Announces Public Filing Of Registration Statement For Proposed U.S. Public Offering
Brief: Innocan Pharma Announces Public Filing Of Registration Statement For Proposed U.S. Public Offering
Brief: Innocan Pharma Reports Lpt-CBD Results in Minipigs, Offers Corporate Update
Brief: Innocan Pharma announces presentation at Painweek Conference
Brief: Innocan Pharma Announces Closing Of Private Placement
Brief: Innocan Pharma Broadens Intellectual Property Coverage for its Liposomal CBD Injection Across Asia and Announces Private Placement of Units
Brief: Innocan Pharma Reports Full Year 2024 Results With Revenues More Than Doubling To Us $29.4 Million
Brief: Innocan Pharma Reports Full Year 2024 Results With Revenues More Than Doubling To Us $29.4 Million
Brief: Innocan Pharma Announces Closing Of Debenture Unit Offering To Its Largest Shareholder, Tamar Innovest Limited
Brief: Innocan Pharma Announces Closing Of Debenture Unit Offering To Its Largest Shareholder, Tamar Innovest Limited
Brief: Innocan Pharma Announces Closing Of Private Placement For Gross Proceeds Of C$635,444.60
Brief: Innocan Pharma Announces Closing Of Private Placement For Gross Proceeds Of C$635,444.60
Brief: Innocan Pharma Announces Private Placement Of Units